TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.99|
|52 Week High||US$9.94|
|52 Week Low||US$35.86|
|1 Month Change||-34.54%|
|3 Month Change||-42.15%|
|1 Year Change||-50.74%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-33.71%|
Recent News & Updates
Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of TCR2 Therapeutics Inc...
|TCRR||US Biotechs||US Market|
Return vs Industry: TCRR underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: TCRR underperformed the US Market which returned 33.8% over the past year.
Stable Share Price: TCRR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: TCRR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company’s lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies.
Is TCR2 Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TCRR ($9.99) is trading below our estimate of fair value ($24.69)
Significantly Below Fair Value: TCRR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TCRR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TCRR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TCRR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TCRR is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.2x).
How is TCR2 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCRR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCRR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCRR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCRR is forecast to have no revenue next year.
High Growth Revenue: TCRR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCRR's Return on Equity is forecast to be high in 3 years time
How has TCR2 Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TCRR is currently unprofitable.
Growing Profit Margin: TCRR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TCRR is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare TCRR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCRR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: TCRR has a negative Return on Equity (-24.69%), as it is currently unprofitable.
How is TCR2 Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: TCRR's short term assets ($325.2M) exceed its short term liabilities ($14.9M).
Long Term Liabilities: TCRR's short term assets ($325.2M) exceed its long term liabilities ($24.3M).
Debt to Equity History and Analysis
Debt Level: TCRR is debt free.
Reducing Debt: TCRR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCRR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TCRR has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 38.9% each year.
What is TCR2 Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TCRR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TCRR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Garry Menzel (57 yo)
Dr. Garry E. Menzel, Ph D., M.B.A. serves as an Independent Director at Black Diamond Therapeutics, Inc. since March 2017. He serves as Director at Stoke Therapeutics, Inc since August 17, 2020.He serves...
CEO Compensation Analysis
Compensation vs Market: Garry's total compensation ($USD6.14M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.
Experienced Management: TCRR's management team is considered experienced (3.2 years average tenure).
Experienced Board: TCRR's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
TCR2 Therapeutics Inc.'s employee growth, exchange listings and data sources
- Name: TCR2 Therapeutics Inc.
- Ticker: TCRR
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$381.581m
- Shares outstanding: 38.20m
- Website: https://www.tcr2.com
Number of Employees
- TCR2 Therapeutics Inc.
- 100 Binney Street
- Suite 710
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 22:13|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.